The truth about GLP-1 medications for weight loss: What every patient should know
For years, weight loss has been sold as a simple math problem: eat less, move more, and the pounds will melt away. But if that were true, we wouldn’t have an obesity epidemic affecting over 40 percent of adults in the U.S.
Now, a new class of medications—GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)—are changing the game. People who have struggled with their weight for …
